BR112021017702A2 - Inibidor contendo anticorpo anti-receptor de il-6 para inibição de deterioração da função bhe - Google Patents

Inibidor contendo anticorpo anti-receptor de il-6 para inibição de deterioração da função bhe

Info

Publication number
BR112021017702A2
BR112021017702A2 BR112021017702A BR112021017702A BR112021017702A2 BR 112021017702 A2 BR112021017702 A2 BR 112021017702A2 BR 112021017702 A BR112021017702 A BR 112021017702A BR 112021017702 A BR112021017702 A BR 112021017702A BR 112021017702 A2 BR112021017702 A2 BR 112021017702A2
Authority
BR
Brazil
Prior art keywords
function
blood
sequence
brain barrier
bhe
Prior art date
Application number
BR112021017702A
Other languages
English (en)
Portuguese (pt)
Inventor
Kenichi Serizawa
Takashi Kanda
Yukio Takeshita
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BR112021017702A2 publication Critical patent/BR112021017702A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021017702A 2019-03-29 2020-02-17 Inibidor contendo anticorpo anti-receptor de il-6 para inibição de deterioração da função bhe BR112021017702A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019068693 2019-03-29
PCT/JP2020/005965 WO2020202839A1 (ja) 2019-03-29 2020-02-17 抗ｉｌ－６受容体抗体を含有するｂｂｂ機能低下の抑制剤

Publications (1)

Publication Number Publication Date
BR112021017702A2 true BR112021017702A2 (pt) 2021-11-16

Family

ID=72667972

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017702A BR112021017702A2 (pt) 2019-03-29 2020-02-17 Inibidor contendo anticorpo anti-receptor de il-6 para inibição de deterioração da função bhe

Country Status (12)

Country Link
US (1) US20220220210A1 (https=)
EP (1) EP3949989A4 (https=)
JP (2) JPWO2020202839A1 (https=)
KR (1) KR20210144795A (https=)
CN (1) CN113660951A (https=)
AU (1) AU2020255449A1 (https=)
BR (1) BR112021017702A2 (https=)
CA (1) CA3133610A1 (https=)
IL (1) IL286716A (https=)
MX (1) MX2021011464A (https=)
TW (1) TWI859192B (https=)
WO (1) WO2020202839A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
EP3957324A4 (en) 2019-04-17 2023-02-08 Hiroshima University THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR
EP4413998A4 (en) * 2021-10-08 2026-02-25 Chugai Pharmaceutical Co Ltd METHOD FOR PREPARING A PRE-FILLED SYRINGE FORMULATION
KR20240145472A (ko) * 2022-01-19 2024-10-07 추가이 세이야쿠 가부시키가이샤 사트랄리주맙을 사용하는 자기면역 뇌염의 치료

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
KR101680906B1 (ko) * 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
SI2315780T1 (sl) * 2008-07-17 2015-11-30 Novartis Ag Sestavki in postopki uporabe za terapevtska protitelesa
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP4809930B2 (ja) 2009-03-19 2011-11-09 中外製薬株式会社 関節リウマチ治療剤
WO2010106812A1 (en) 2009-03-19 2010-09-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation containing improved antibody molecules
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
AU2012322721B2 (en) * 2011-10-11 2016-05-05 Vaccinex, Inc. Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
EP3185004A4 (en) * 2014-08-20 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
US11447752B2 (en) 2016-04-15 2022-09-20 Yamaguchi University In vitro model for blood-brain barrier and method for producing in vitro model for blood-brain barrier

Also Published As

Publication number Publication date
TW202102540A (zh) 2021-01-16
TWI859192B (zh) 2024-10-21
WO2020202839A1 (ja) 2020-10-08
EP3949989A4 (en) 2022-12-14
JP2024102154A (ja) 2024-07-30
CN113660951A (zh) 2021-11-16
AU2020255449A1 (en) 2021-10-07
JPWO2020202839A1 (https=) 2020-10-08
CA3133610A1 (en) 2020-10-08
MX2021011464A (es) 2021-10-22
IL286716A (en) 2021-12-01
EP3949989A1 (en) 2022-02-09
US20220220210A1 (en) 2022-07-14
KR20210144795A (ko) 2021-11-30

Similar Documents

Publication Publication Date Title
BR112021017702A2 (pt) Inibidor contendo anticorpo anti-receptor de il-6 para inibição de deterioração da função bhe
RU2018134065A (ru) Антитела, специфические к рецептору полиовируса (pvr) человека
JP2021522801A5 (https=)
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
JP2018508483A5 (https=)
JP2018515532A5 (https=)
AR109882A1 (es) Anticuerpos monoclonales neutralizantes anti-tl1a
MX2020012567A (es) Anticuerpos anti-ox40 y metodos de uso.
BR112017026189A2 (pt) tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4
IL253462B (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
ZA202202363B (en) Antibodies against ilt2 and use thereof
JP2022519341A5 (https=)
JP2014529610A5 (https=)
AR096601A1 (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
BR112018002436A2 (pt) tratamento de combinação de usos de métodos destes
AR123671A1 (es) Anticuerpo fn14 anti-humano
RU2017112967A (ru) Лечение и функциональное излучение вич-инфекции моноклональными антителами к cd4, опосредующими конкуретное ингибирование входа вич
Castro et al. Induction versus noninduction therapy in kidney transplantation: considering different PRA levels and different induction therapies
RU2018146778A (ru) Режим дозирования антитела к c5
Lavasani et al. Monoclonal Antibody against T‐Cell Receptor αβ Induces Self‐Tolerance in Chronic Experimental Autoimmune Encephalomyelitis
Lee et al. Effectiveness of antithymocyte globulin induction dosing regimens in kidney transplantation patients: a network meta-analysis
MX2021005686A (es) Combinacion farmaceutica de anti-ceacam6 y anticuerpos anti-pd-1 o anti-pd-l1 para el tratamiento del cancer.
Berga et al. Desensitization protocol in recipients of deceased kidney donor with donor-specific antibody–low titers
Lobbes et al. Efficacy of bortezomib in non‐IgM type I cryoglobulinaemic vasculitis: a single‐centre retrospective case series
Jalalonmuhali et al. Low immunologic risk living related renal transplant using very low-dose antithymocyte globulin as induction therapy: A single tertiary hospital experience

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]